khdrbs2 Antibody

What is KHDRBS2 and what cellular functions does it regulate?

KHDRBS2 (KH RNA Binding Domain Containing, Signal Transduction Associated 2), also known as SLM-1 or SLM1, functions as a key regulator of RNA processing and alternative splicing. This nuclear protein plays crucial roles in post-transcriptional gene regulation, impacting diverse cellular processes including cell proliferation, apoptosis, and tumorigenesis. KHDRBS2 contains an RNA-binding KH domain that allows it to interact with target RNA sequences and influence their processing and fate within the cell .

The protein evolved through whole genome duplication (WGD) events, which is relevant to understanding its evolutionary relationships with paralogous genes like KHDRBS3 . At the cellular level, KHDRBS2 primarily localizes to the nucleus, where it participates in RNA metabolism pathways . Dysregulation of KHDRBS2 has been implicated in various pathological conditions, including cancer, neurodegenerative disorders, and viral infections .

What are the typical applications for KHDRBS2 antibodies in research?

KHDRBS2 antibodies are versatile tools that support multiple experimental applications for researchers investigating this protein's expression, localization, and function:

These applications allow researchers to detect, quantify, and visualize KHDRBS2 protein in diverse experimental contexts . When designing experiments, it's important to validate antibody specificity and optimize protocols for your specific cell or tissue type.

How does the molecular weight of KHDRBS2 impact experimental interpretation?

The theoretical calculated molecular weight of KHDRBS2 is approximately 38 kDa, while the observed molecular weight in Western blot experiments is typically around 39 kDa . This discrepancy is not uncommon in protein research and warrants consideration when analyzing experimental results.

The difference between calculated and observed molecular weights can be attributed to several factors:

• Post-translational modifications (PTMs) such as phosphorylation, which can alter protein mobility during electrophoresis

• The presence of multiple protein isoforms or modified forms simultaneously in samples

• The impact of protein structure on migration patterns in SDS-PAGE

When multiple bands appear on a Western blot, this could indicate different modified forms of KHDRBS2 rather than non-specific binding . Understanding these variations is critical for accurate experimental interpretation and troubleshooting.

What are the optimal protocols for using KHDRBS2 antibodies in Western blotting experiments?

For robust Western blot analysis of KHDRBS2, researchers should consider the following methodological approach:

• Sample Preparation:

  • Extract proteins using phosphate buffered solutions (PBS) containing protease inhibitors

  • Denature samples in standard loading buffer containing SDS and β-mercaptoethanol

  • Load 20-40 μg of total protein per lane for cell lysates

• Electrophoresis and Transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation around the 39 kDa range

  • Transfer to PVDF or nitrocellulose membranes using standard protocols

• Antibody Incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • Dilute primary KHDRBS2 antibody 1:500-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash thoroughly with TBST buffer (3-5 times, 5-10 minutes each)

  • Incubate with appropriate HRP-conjugated secondary antibody

• Signal Detection:

  • Use ECL reagents for visualization

  • Expected band size: 39 kDa

Positive control samples should include lysates from HeLa, 293T, Jurkat, or K562 cell lines, which have been validated to express detectable levels of KHDRBS2 .

How can researchers design experiments to study KHDRBS2 function in RNA processing?

To investigate KHDRBS2's role in RNA processing and alternative splicing, consider implementing these methodological approaches:

• RNA Immunoprecipitation (RIP):

  • Use validated KHDRBS2 antibodies to immunoprecipitate the protein along with its bound RNA targets

  • Analyze precipitated RNA by RT-PCR or RNA-seq to identify KHDRBS2-associated transcripts

  • Include appropriate controls (IgG, input samples)

• Alternative Splicing Analysis:

  • Design RT-PCR primers flanking known or predicted alternatively spliced exons

  • Compare splicing patterns in cells with normal vs. altered KHDRBS2 expression

  • Use quantitative PCR methods similar to those described in the literature: 95°C for 15s, followed by 40 cycles of 95°C for 15s, 60°C for 15s, and 72°C for 35s

  • Calculate relative expression using the comparative threshold cycle (CT) method (2-ΔΔCt)

• KHDRBS2 Knockdown/Overexpression:

  • Utilize siRNA or CRISPR-Cas9 to reduce KHDRBS2 expression

  • Use expression vectors for overexpression studies

  • Confirm knockdown/overexpression efficiency by Western blot using validated antibodies

  • Examine effects on target RNA processing and cellular phenotypes

This multi-faceted approach allows researchers to comprehensively study KHDRBS2's functional role in RNA metabolism pathways .

What considerations are important when using KHDRBS2 antibodies for immunohistochemistry studies?

For successful immunohistochemistry (IHC) analysis of KHDRBS2 in tissue samples:

• Tissue Preparation:

  • For paraffin-embedded tissues, perform standard deparaffinization and rehydration

  • Consider heat-induced epitope retrieval (HIER) in citrate buffer (pH 6.0) or EDTA buffer (pH 8.0)

  • Block endogenous peroxidase activity with hydrogen peroxide solution

• Antibody Application:

  • Dilute KHDRBS2 antibody at 1:100-1:200 as recommended

  • Incubate overnight at 4°C in a humidified chamber

  • Use validated positive control tissues such as human prostate cancer, esophagus, or stomach tissues

  • Include appropriate negative controls (omitting primary antibody)

• Signal Detection and Analysis:

  • Use appropriate detection systems (HRP/DAB for brightfield, fluorescent secondaries for IF)

  • Examine for nuclear localization, which is the expected cellular compartment for KHDRBS2

  • Analyze signal intensity and distribution patterns across different cell types within the tissue

• Result Interpretation:

  • Compare expression patterns with known literature

  • Consider counterstaining with hematoxylin or DAPI to visualize tissue architecture

  • Document findings with high-quality microscopy images at appropriate magnifications (e.g., 40x as shown in product data)

These methodological considerations ensure reliable and reproducible IHC results when studying KHDRBS2 expression in tissue samples.

How can researchers address discrepancies in KHDRBS2 antibody Western blot results?

When experiencing unexpected results or discrepancies in Western blot experiments:

• Multiple or Unexpected Bands:

  • If detecting multiple bands, consider post-translational modifications or protein isoforms

  • The mobility of proteins in SDS-PAGE can be affected by many factors that cause observed band size to be inconsistent with expectations

  • Verify antibody specificity using known positive controls (HeLa, 293T, Jurkat, K562)

  • Consider using protein samples from KHDRBS2 knockout or knockdown models as negative controls

• Weak or No Signal:

  • Optimize antibody concentration (try a range of dilutions)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Increase protein loading amount (50-100 μg)

  • Use more sensitive detection methods (enhanced chemiluminescence)

  • Verify target protein expression in your experimental system

• High Background:

  • Increase blocking time and concentration (5% BSA or milk)

  • Add 0.1-0.3% Tween-20 to washing buffers

  • Decrease secondary antibody concentration

  • Ensure thorough washing between steps (5-6 washes of 5-10 minutes each)

• Optimization Strategies:

  • Test alternative lysis buffers to improve protein extraction

  • Consider using gradient gels for better separation

  • Validate with alternative KHDRBS2 antibodies that recognize different epitopes

These troubleshooting approaches help resolve common technical issues in Western blot analysis of KHDRBS2 .

What experimental controls are essential when studying KHDRBS2 using antibody-based methods?

Rigorous experimental controls are critical for reliable KHDRBS2 research:

• Positive Controls:

  • Cell lines with known KHDRBS2 expression: HeLa, 293T, Jurkat, K562 cell lysates

  • Tissues with documented KHDRBS2 expression: human prostate cancer, esophagus, stomach tissues

  • Recombinant KHDRBS2 protein (for antibody validation)

• Negative Controls:

  • Isotype-matched IgG controls for immunoprecipitation experiments

  • KHDRBS2 knockdown or knockout samples

  • Tissues known to have low or no KHDRBS2 expression

  • Primary antibody omission controls in IHC/IF

• Specificity Controls:

  • Peptide competition assays using the immunogenic peptide

  • Testing antibody reactivity across multiple species if performing comparative studies

  • Validation with multiple antibodies targeting different epitopes of KHDRBS2

• Housekeeping Controls:

  • For quantitative expression analysis, include appropriate housekeeping genes like β-actin and EF1-α for normalization in qRT-PCR

  • Load controls such as GAPDH, β-actin, or total protein staining for Western blot normalization

Implementing these controls helps ensure experimental rigor and reproducibility in KHDRBS2 research.

What is known about KHDRBS2's evolutionary relationship with its paralogous genes?

KHDRBS2 belongs to a family of KH domain-containing RNA-binding proteins that evolved through whole genome duplications (WGD). Current research provides several key insights:

• Evolutionary Origins:

  • KHDRBS genes were generated by whole genome duplications, contributing to vertebrate morphological novelties

  • Bayesian phylogenetic analysis has been used to establish evolutionary relationships between KHDRBS family members

  • Synteny data analysis helps track the genomic positioning and evolutionary history of these genes

• Paralogous Relationships:

  • KHDRBS3 is an important paralog of KHDRBS2

  • These paralogs likely arose from gene duplication events and have subsequently diverged in function

  • Comparative analysis of domain structures and expression patterns can reveal functional specialization

• Structural Conservation:

  • Analysis of gene structural features and protein domains using tools like SMART reveals conservation patterns across family members

  • The KH domain represents a highly conserved functional element crucial for RNA-binding activity

This evolutionary context provides valuable insight into KHDRBS2 function and can guide comparative studies across species and related gene family members.

What disease associations have been identified for KHDRBS2, and how might this direct future research?

KHDRBS2 has been implicated in several pathological conditions, suggesting multiple avenues for future investigation:

• Cardiovascular Disorders:

  • KHDRBS2 has been associated with Atrial Septal Defect 2, indicating potential roles in cardiac development or function

  • Further research might explore its role in heart development or cardiac pathophysiology

• Cancer Biology:

  • KHDRBS2 has been studied in the context of various cancers, including prostate cancer

  • Its role in post-transcriptional gene regulation suggests potential involvement in oncogenic pathways

  • Research areas include examining KHDRBS2 expression in different cancer types and investigating its regulation of cancer-associated alternative splicing events

• Neurological Disorders:

  • KHDRBS2's involvement in RNA processing suggests potential roles in neurodegenerative conditions

  • Future studies might investigate its expression and function in neuronal tissues and neurological disease models

• Signaling Pathway Integration:

  • KHDRBS2 is linked to signaling by GPCR and PTK6 pathways

  • Research into how KHDRBS2 integrates these signaling events with RNA processing could reveal novel regulatory mechanisms

These disease associations provide rationale for therapeutic targeting strategies and biomarker development in future translational research.

What methodological advances might enhance KHDRBS2 research in coming years?

Emerging technologies and methodological approaches promise to advance KHDRBS2 research:

• Single-Cell Technologies:

  • Single-cell RNA sequencing can reveal cell-type-specific expression patterns of KHDRBS2

  • Single-cell protein analysis methods may uncover heterogeneity in KHDRBS2 function across different cell populations

• Advanced Imaging Techniques:

  • Super-resolution microscopy for detailed subcellular localization studies

  • Live-cell imaging with fluorescently tagged KHDRBS2 to study dynamic protein interactions

  • Proximity labeling approaches to identify protein interaction networks in native cellular contexts

• Functional Genomics Approaches:

  • CRISPR-Cas9 screens to identify genetic interactions with KHDRBS2

  • CRISPR-based approaches for tagging endogenous KHDRBS2 for functional studies

  • Conditional knockout models to study tissue-specific functions

• RNA-Protein Interaction Analysis:

  • CLIP-seq (Cross-linking immunoprecipitation sequencing) to map KHDRBS2-RNA interactions at high resolution

  • Structural studies of KHDRBS2-RNA complexes using cryo-EM or X-ray crystallography

  • RNA structure probing techniques to understand how KHDRBS2 binding affects RNA conformation

These methodological advances will provide deeper insights into KHDRBS2 biology and potentially reveal new therapeutic targets or diagnostic approaches.

What are the optimal storage and handling conditions for KHDRBS2 antibodies?

To maintain antibody integrity and performance over time:

• Storage Recommendations:

  • Store KHDRBS2 antibodies at -20°C for long-term storage

  • Antibodies are typically supplied in phosphate buffered solution (pH 7.4) containing stabilizers (0.05%) and glycerol (50%)

  • Valid for approximately 12 months when properly stored

  • Avoid repeated freeze/thaw cycles which can degrade antibody quality

• Shipping and Receipt Handling:

  • Antibodies are typically shipped with ice packs

  • Upon receipt, immediately store at recommended temperature (-20°C)

  • Briefly centrifuge vials before opening to ensure complete recovery of contents

• Working Solution Preparation:

  • Prepare working dilutions on the day of use or store at 4°C for short periods (1-2 days)

  • Return stock solution to -20°C promptly after use

  • Consider preparing small aliquots to minimize freeze/thaw cycles

These storage and handling practices ensure optimal antibody performance in experimental applications.

How can researchers effectively validate KHDRBS2 antibodies for their specific experimental systems?

Robust validation ensures reliable results when using KHDRBS2 antibodies:

• Initial Validation Steps:

  • Confirm reactivity with recombinant KHDRBS2 protein

  • Test in cell lines with known KHDRBS2 expression (HeLa, 293T, Jurkat, K562)

  • Verify expected molecular weight (39 kDa) in Western blot applications

  • Confirm expected subcellular localization (nuclear) in immunofluorescence or IHC applications

• Advanced Validation Approaches:

  • Perform siRNA knockdown experiments to demonstrate reduction in antibody signal

  • Use CRISPR/Cas9-generated KHDRBS2 knockout cells as negative controls

  • Conduct peptide competition assays with the immunogenic peptide used to generate the antibody

  • Compare results with multiple antibodies targeting different epitopes of KHDRBS2

• Species Cross-Reactivity Testing:

  • Validate reactivity in target species (common reactivity includes human and mouse)

  • If working with other species, conduct preliminary testing before full experimental implementation

• Application-Specific Validation:

  • For each application (WB, IHC, IF, etc.), perform targeted optimization and validation steps

  • Document optimal conditions for future reference

Thorough validation ensures confidence in experimental results and facilitates troubleshooting if unexpected results occur.